Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 25, 2026 16:15 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics to Join the Russell 3000® Index

MILLBRAE, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to...
June 08, 2026 08:00 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors

MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to...
May 30, 2026 14:30 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease...
May 21, 2026 17:05 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

The six accepted presentations highlight clinical progress across Eikon’s pipeline.
May 11, 2026 16:01 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus...
March 30, 2026 07:48 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates

Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
February 04, 2026 19:59 ET | Source: Eikon Therapeutics, Inc.

Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering

MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to...